Cancer drug trial halted: AUR 109 shows mixed early results

NCT ID NCT06760702

First seen Apr 28, 2026 · Last updated May 14, 2026 · Updated 4 times

Summary

This study tested three different doses of an experimental drug called AUR 109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. However, the trial was stopped early, so the full results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Gindodi Devi Hospital

    Khursīpār, Chhattisgarh, 490012, India

  • Kiran Multi Super Speciality Hospital and Research Centre

    Surat, Gujarat, 395004, India

  • Sujan Surgical Cancer Hospital and Amravati Cancer Foundation

    Amravati, Maharashtra, 444605, India

  • Sunshine Global Hospitals

    Surat, Gujarat, 395007, India

  • Uro-Science Centre, S.P. Medical College & AG of Hospitals

    Bikaner, Rajasthan, 334003, India

Conditions

Explore the condition pages connected to this study.